Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Canakinumab reverses overexpression of inflammatory response genes in tumour necrosis factor receptor-associated periodic syndrome.

Annals of the rheumatic diseases - 1 Jan 2017

Torene Rebecca, Nirmala Nanguneri, Obici Laura, Cattalini Marco, Tormey Vincent, Caorsi Roberta, Starck-Schwertz Sandrine, Letzkus Martin, Hartmann Nicole, Abrams Ken, Lachmann Helen, Gattorno Marco

Abstract excerpt

OBJECTIVE: To explore whether gene expression profiling can identify a molecular mechanism for the clinical benefit of canakinumab treatment in patents with tumour necrosis factor receptor-associated periodic syndrome (TRAPS). METHODS: Blood samples were collected from 20 patients with active TRAPS who received canakinumab 150 mg every 4 weeks for 4 months in an open-label proof-of-concept phase II study, and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Administration Schedule

Share to Familial Mediterranean Fever

Share to Interleukin-1beta

Share to Leukocyte Count

Share to Neutrophils

Share to Receptors, Tumor Necrosis Factor

Source

Open in PubMed Open full text

Identifiers

PMID: 27474763
DOI: 10.1136/annrheumdis-2016-209335
PMCID: PMC5264306

Genes

MAPK14
TNF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Canakinumab reverses overexpression of inflammatory response genes in tumour necrosis factor receptor-associated periodic syndrome.PMID 27474763Read ↗

Canakinumab for the treatment of TNF-receptor associated periodic syndrome.Semantic proximity Read ↗

Tumor necrosis factor receptor-associated periodic syndrome managed with the couple canakinumab-alendronate.Semantic proximity Read ↗

Delights and let-downs in the management of tumor necrosis factor receptor-associated periodic syndrome: the canakinumab experience in a patient with a high-penetrance T50M TNFRSF1A variant.Semantic proximity Read ↗

Gene expression profile in TNF receptor-associated periodic syndrome reveals constitutively enhanced pathways and new players in the underlying inflammation.Semantic proximity Read ↗

A signalome screening approach in the autoinflammatory disease TNF receptor associated periodic syndrome (TRAPS) highlights the anti-inflammatory properties of drugs for repurposing.Semantic proximity Read ↗

Canakinumab efficacy and long-term tocilizumab administration in tumor necrosis factor receptor-associated periodic syndrome (TRAPS).Semantic proximity Read ↗

Novel markers of inflammation identified in tumor necrosis factor receptor-associated periodic syndrome (TRAPS) by transcriptomic analysis of effects of TRAPS-associated tumor necrosis factor receptor type I mutations in an endothelial cell line.Semantic proximity Read ↗

Key facts and hot spots on tumor necrosis factor receptor-associated periodic syndrome.Semantic proximity Read ↗

Candidate genes in patients with autoinflammatory syndrome resembling tumor necrosis factor receptor-associated periodic syndrome without mutations in the TNFRSF1A gene.Semantic proximity Read ↗

Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapySemantic proximity Read ↗

Clinical Characteristics of Cryopyrin-Associated Periodic Syndrome and Long-Term Real-World Efficacy and Tolerability of Canakinumab in Japan: Results of a Nationwide Survey.Semantic proximity Read ↗

the tumour necrosis factor receptor-associated periodic syndrome: current conceptsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.